Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 8/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30212090 | 0.91 | FASN (1.00) | FASNKDM4EMEN1AKR1B10ALOX5 | |
| SCHEMBL30212070 | 0.88 | FASN (0.82) | FASNKDM4EMEN1AKR1B10ALOX5 | |
| SCHEMBL30212099 | 0.80 | FASN (0.91) | FASNALDH1A1KDM4EMEN1AKR1B10 | |
| SCHEMBL29466102 | 0.78 | FASN (0.91) | FASNALOX5 | |
| SCHEMBL28043703 | 0.77 | FASN (0.89) | FASNALOX5 | |
| SCHEMBL30212096 | 0.76 | FASN (1.00) | FASN | |
| SCHEMBL30212074 | 0.75 | FASN (0.56) | FASNALOX5 | |
| SCHEMBL30212075 | 0.75 | FASN (0.53) | FASNALDH1A1KDM4EMEN1ALOX5 | |
| SCHEMBL30212041 | 0.75 | FASN (0.80) | FASNALOX5 | |
| SCHEMBL30212065 | 0.74 | FASN (0.72) | FASNALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178790-B2 | Antibacterial compound isolated from Psiloxylon mauritianum and its derivatives | SORRES, Jonathan (FR) | 2024-12-31 | — | — | US | disclosed |
| CN-116270567-A | Pharmaceutical preparation for treating diabetes | 山东中医药大学附属医院 | 2023-06-23 | — | — | CN | disclosed |
| US-20230062900-A1 | NEW ANTIBACTERIAL COMPOUND ISOLATED FROM PSILOXYLON MAURITIANUM AND ITS DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2023-03-02 | — | — | US | disclosed |
| CN-106038900-A | Medicine composition for treating diabetic nephropathy and preparation method thereof | 济南星懿医药技术有限公司 | 2016-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062900-A1 | NEW ANTIBACTERIAL COMPOUND ISOLATED FROM PSILOXYLON MAURITIANUM AND ITS DERIVATIVES | PNN, AAAS, MRPS35 | FASN 37/4885ALDH1A1 2230/4885POLB 1460/4885 |
| US-12178790-B2 | Antibacterial compound isolated from Psiloxylon mauritianum and its derivatives | AAAS, PNN, MRPL9 | FASN 27/4885ALDH1A1 2151/4885POLB 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.